Equities

IXICO PLC

IXI:LSE

IXICO PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10.25
  • Today's Change0.00 / 0.00%
  • Shares traded73.59k
  • 1 Year change-12.77%
  • Beta1.1277
Data delayed at least 20 minutes, as of Feb 06 2026 16:12 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year IXICO PLC grew revenues 13.32% from 5.77m to 6.53m while net income improved from a loss of 2.00m to a smaller loss of 1.65m.
Gross margin48.71%
Net profit margin-25.27%
Operating margin-39.09%
Return on assets-13.19%
Return on equity-15.57%
Return on investment-15.43%
More ▼

Cash flow in GBPView more

In 2025, IXICO PLC increased its cash reserves by 97.93%, or 1.75m. Cash Flow from Financing totalled 3.50m or 53.61% of revenues. In addition the company used 1.01m for operations while cash used for investing totalled 746.00k.
Cash flow per share-0.0139
Price/Cash flow per share--
Book value per share0.1267
Tangible book value per share0.0491
More ▼

Balance sheet in GBPView more

IXICO PLC appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio3.03
Quick ratio--
Total debt/total equity0.0153
Total debt/total capital0.015
More ▼

Growth rates in GBP

Year on year, growth in earnings per share excluding extraordinary items increased 55.46%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		55.10
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.